Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-01-25
2005-01-25
Epps-Ford, Janet L. (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C536S024300, C536S024310, C536S024330
Reexamination Certificate
active
06846921
ABSTRACT:
Chimeric oligonucleotide of the formula 5′-W—X1—Y—X2—Z-3′, where W represents a 5′-O-alkyl nucleotide, each of X1and X2represents a block of seven to twelve phosphodiester-linked 2′-O-alkyl ribonucleotides, Y represents a block of five to twelve phosphorothioate-linked deoxyribonucleotides, and Z represents a blocking group effective to block nuclease activity at the 3′ end of the oligonucleotide, are described. These compounds exhibit high resistance to endo- and exonucleases, high sequence specificity, and the ability to activate RNAse H, as evidenced by efficient and long-lasting suppression of target mRNA. The oligonucleotides are preferably transfected into cells in formulations containing a lipid-peptoid conjugate carrier molecule of the formulain-line-formulae description="In-line Formulae" end="lead"?L-linker-[N(CH2CH2NH2)CH2(C═O)—N(CH2CH2R)CH2(C═O)—N(CH2CH2R)CH2(C═O)]3—NH2,in-line-formulae description="In-line Formulae" end="tail"?where L is a lipid moiety, including a steroid, and each group R is independently selected from alkyl, aminoalkyl, and aralkyl.
REFERENCES:
patent: 5576208 (1996-11-01), Monia et al.
patent: 5849902 (1998-12-01), Arrow et al.
patent: 5958773 (1999-09-01), Monia et al.
patent: 6355418 (2002-03-01), Schmidt
patent: 19750702 (1997-11-01), None
patent: WO 9813526 (1998-04-01), None
patent: WO 9927086 (1999-06-01), None
Monica, Brett P. et. al., “Evaluation of 2′-Modified Oligonucleotides Containing 2″-Deoxy Gaps as Antisense Inhibitors of Gene Expression”,The Journal of Biological Chemistry, vol. 268, No. 19, pp. 14514-14522, Jul. 5, 1993.
Monica, Brett P. et al., “Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras*”, The Journal of Biological Chemistry, vol. 271, No. 24, pp. 14533-14540, Jun. 14, 1996.
Dahma, Mased J. et al., “Antisense L/D-Oligodeoxynucleotide Chimeras: Nuclease Stability, Base-Pairing Properties, and Activity at Directing Robonuclease H†‡”,Biochemistry33, pp. 7877-7885, 1994.
Bhan, Purshotam et al., “2′5′-Linked oligo-3′-deoxyribonucleoside phosphorothioate chimeras: thermal stability and antisense inhibition of gene expression”,Nuclear Acids Research, vol. 25, No. 16, pp. 3310-3317, 1997.
Agrawal, Sudhir et al., “Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies”,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 2620-2625, Mar. 1997.
Shen, Ling X. et al., “Impact of Mixed-backbone Oligonucleotides on Target Binding Affinity and Target Cleaving Specificity and Selectivity byEscherichia coliRNase H”,Bioorganic&Medicinal Chemistry 6, pp. 1695-1705, 1998.
Atabekov, K. J. et al., “Site-specific enzymatic cleavage ot TMV RNA directed by deoxyribo- and chimeric (deoxyribo-ribo) oligonucleotides”,FEBS Lett., vol. 232, No. 1, pp. 96-98, May, 1988.
Yu, Dong et al., “Hybrid Oligonucleotides: Synthesis, Biophysical Properties, Stability Studies, and Biological Activity”,Bioorganic&Medicinal Chemistry, vol. 4, No. 10, pp. 1685-1692, 1996.
Innis Michael A.
Reinhard Christoph J.
Zuckermann Ronald N.
Blackburn Robert P.
Chiron Corporation
Collier Steven W.
Epps-Ford Janet L.
Gorthey LeeAnn
LandOfFree
Chimeric antisense oligonucleotides and cell transfecting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric antisense oligonucleotides and cell transfecting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antisense oligonucleotides and cell transfecting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3417069